Saturday 17 October 2026
Export MNPR’s income statement to Excel — free account
Monopar Therapeutics Inc.
MNPR Healthcare Biotechnology
In the quarter to June 2026, EPS fell 77.1% and free cash flow fell 201.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
69.27
2.53
−3.52%
Follow MNPR
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | 41.75 | 21.40 | 15.10 | 6.96 | 1.37 | 1.55 | 21.00 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | 240.00 | 115.00 | 85.05 | 24.40 | 19.10 | 38.50 | 105.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | 5 | 5 | 10 | 10 | 12 | 10 | 16 | 22 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | (1) | (17) | (3) | (4) | (6) | (9) | (11) | (8) | (16) | (14) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (1) | (17) | (3) | (4) | (6) | (9) | (11) | (8) | (16) | (14) | |||||
| Depreciation | — | — | — | — | — | — | — | — | 0 | (1) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (0.11) | (9.43) | (1.74) | (2.25) | (2.90) | (3.65) | (4.15) | (3.05) | (4.11) | (1.85) | |||||
| Cash flow | (0.11) | (1.50) | (1.44) | (1.62) | (2.13) | (2.93) | (2.84) | (2.84) | (1.69) | (1.65) | |||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (0.11) | (1.50) | (1.44) | (1.62) | (2.13) | (2.93) | (2.84) | (2.84) | (1.69) | (1.65) | |||||
| Book value | 0.27 | 5.48 | 3.72 | 6.77 | 7.16 | 7.59 | 3.97 | 2.02 | 14.52 | 18.60 | |||||
| Shares, m | 11 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 7 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (1) | (3) | (3) | (3) | (5) | (7) | (7) | (8) | (6) | (12) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | (1) | (3) | (3) | (3) | (5) | (7) | (7) | (8) | (6) | (12) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 2 | 9 | 7 | 13 | 16 | 19 | 10 | 6 | 55 | 138 | ||||
| Total debt | — | — | — | — | — | — | 0 | — | — | — | |||||
| Net debt | (2) | (9) | (7) | (13) | (17) | (20) | (13) | (7) | (60) | (140) | |||||
| Shareholders’ equity | 3 | 10 | 7 | 13 | 16 | 19 | 10 | 6 | 55 | 138 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (18.49) | (258.13) | (37.43) | (40.88) | (41.72) | (48.69) | (62.32) | (81.68) | (46.09) | (13.65) | ||||
| ROIC | 0.00 | (1,627.75) | (8,132.57) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (19.05) | (265.94) | (39.04) | (43.23) | (44.52) | (52.57) | (72.44) | (107.19) | (51.42) | (14.22) | |||||
Negative figures in brackets.
Charts ten years each
Monopar Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics Inc. | $481.9M | — (loss-making) | — | — | n/m | −201.41% (below 0%: shrinking) | — | 0.00% | |
| ENTX Entera Bio Ltd. | $481.5M | — (loss-making) | — (loss-making) | +200.00% (above 0%: growing) | n/m | −108.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NGNE Neurogene Inc. | $479.3M | — (loss-making) | — (loss-making) | — | n/m | −22.97% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| YDES YD Bio Limited | $477.5M | — | — | — | — | — | — | — | Compare |
| RGNX REGENXBIO Inc. | $472.7M | — (loss-making) | — (loss-making) | +405.73% (above 0%: growing) | n/m | −26.67% (below 0%: shrinking) | 99.04% | 27.09% | Compare |
| ARVN Arvinas, Inc. | $468.2M | 53.6× | — (loss-making) | +1,014.73% (above 0%: growing) | n/m | +49.79% (above 0%: growing) | 96.40% | 65.72% | Compare |
| CBIO Crescent Biopharma, Inc. | $463.6M | — (loss-making) | — (loss-making) | +1,038,900.00% (above 0%: growing) | n/m | −7.04% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ALLO Allogene Therapeutics, Inc. | $463.0M | — (loss-making) | — (loss-making) | +20,990.91% (above 0%: growing) | n/m | +17.73% (above 0%: growing) | 100.00% | (1,011.21%) | Compare |
| ALT Altimmune, Inc. | $459.1M | — (loss-making) | — (loss-making) | +520.00% (above 0%: growing) | n/m | −25.27% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $470.4M | — | — | +767.37% | — | −22.97% | 100.00% | 0.00% |
Monopar Therapeutics Inc. (MNPR) key facts
- Monopar Therapeutics Inc. (MNPR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, MNPR traded at $69.27, a market capitalization of $481.9 million.
- Return on equity was −14.2% and debt-to-equity 0.00.